Thermo Fisher Scientific Bevacizumab Monoclonal Antibody (6C3)

Applications

Tested Dilution

Publications

ELISA (ELISA)

0.01-0.1 µg/mL

-

Blocking Assay (BLOCK)

0.1-10 µg/mL

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Mouse / IgG1

Class

Monoclonal

Type

Antibody

Clone

6C3

Immunogen

Bevacizumab

Conjugate

Unconjugated Unconjugated Unconjugated

View additional formats

• Biotin
• Request custom conjugation

Form

Lyophilized

Purification

Protein A

Storage buffer

PBS, pH 7.4

Contains

0.02% sodium azide

Storage conditions

-20°C or -80°C if preferred

Shipping conditions

Ambient (domestic); Wet ice (international)

Product Specific Information

Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.

Bevacizumab (Avastin) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of a number of types of cancers and a specific eye disease. Bevacizumab binds a continuous epitope in VEGF, preventing interaction of VEGF with VEGFR on the surface of endothelial cells. It can be used to inhibit solid tumour growth and metastasis by weakening tumour angiogenesis.
Anti-Bevacizumab Antibody (6C3), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Bevacizumab.

Target Information

Bevacizumab (Avastin) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with colon cancer, lung cancer, glioblastoma, renal-cell carcinoma, and age-related macular degeneration. As angiogenesis inhibitor, Bevacizumab blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.